Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

The nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI.

The beta nerve growth factor drugs in development market report provides an in-depth analysis of Beta NGF or NGF targeted pipeline therapeutics. The report provides comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Beta NGF targeted therapeutics development with respective active and dormant or discontinued projects.

What are the mechanisms of action of the Beta NGF pipeline drugs market?

The mechanisms of action of the Beta NGF pipeline drugs market are Beta Nerve Growth Factor Inhibitor, Beta Nerve Growth Factor Activator, Tumor Necrosis Factor Inhibitor, and Brain Derived Neurotrophic Factor Activator.

Beta NGF pipeline drugs market, by mechanisms of action

Beta NGF pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Beta NGF pipeline drugs market?

The routes of administration in the Beta NGF pipeline drugs market are subcutaneous, intravenous, ophthalmic, parenteral, and intramuscular.

Beta NGF pipeline drugs market, by routes of administration

Beta NGF pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Beta NGF pipeline drugs market?

The molecule types in the Beta NGF pipeline drugs market are monoclonal antibody, small molecule, aptamer, gene therapy, and recombinant protein.

Beta NGF pipeline drugs market, by molecule types

Beta NGF pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Beta NGF pipeline drugs market?

Some of the key companies in the Beta NGF pipeline drugs market are Akeso Inc, AstraZeneca Plc, Chengdu Easton Biopharmaceuticals Co Ltd, Dartsbio Pharmaceutical (Guangdong) Co Ltd, Fujimoto Pharmaceutical Corp, MimeTech Srl, Regeneron Pharmaceuticals Inc, Shandong Boan Biotechnology Co Ltd, Staidson BioPharma Inc, and Zhuhai Trinomab Biotechnology Co Ltd.

Beta NGF pipeline drugs market, by key companies

Beta NGF pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Mechanisms of Action Beta Nerve Growth Factor Inhibitor, Beta Nerve Growth Factor Activator, Tumor Necrosis Factor Inhibitor, and Brain Derived Neurotrophic Factor Activator
Routes of Administration Subcutaneous, Intravenous, Ophthalmic, Parenteral, and Intramuscular
Molecule Types Monoclonal Antibody, Small Molecule, Aptamer, Gene Therapy, and Recombinant Protein
Key Companies Akeso Inc, AstraZeneca Plc, Chengdu Easton Biopharmaceuticals Co Ltd, Dartsbio Pharmaceutical (Guangdong) Co Ltd, Fujimoto Pharmaceutical Corp, MimeTech Srl, Regeneron Pharmaceuticals Inc, Shandong Boan Biotechnology Co Ltd, Staidson BioPharma Inc, and Zhuhai Trinomab Biotechnology Co Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Beta Nerve Growth Factor (Beta NGF or NGF).
  • Reviews of pipeline therapeutics for Beta Nerve Growth Factor (Beta NGF or NGF) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Beta Nerve Growth Factor (Beta NGF or NGF) therapeutics and enlists all their major and minor projects.
  • Evaluation of Beta Nerve Growth Factor (Beta NGF or NGF) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Beta Nerve Growth Factor (Beta NGF or NGF).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Beta Nerve Growth Factor (Beta NGF or NGF).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Akeso Inc
AstraZeneca Plc
Chengdu Easton Biopharmaceuticals Co Ltd
Dartsbio Pharmaceutical (Guangdong) Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Regeneron Pharmaceuticals Inc
Shandong Boan Biotechnology Co Ltd
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF) – Overview

Beta Nerve Growth Factor (Beta NGF or NGF) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) – Companies Involved in Therapeutics Development

Akeso Inc

AstraZeneca Plc

Chengdu Easton Biopharmaceuticals Co Ltd

Dartsbio Pharmaceutical (Guangdong) Co Ltd

Fujimoto Pharmaceutical Corp

MimeTech Srl

Regeneron Pharmaceuticals Inc

Shandong Boan Biotechnology Co Ltd

Staidson BioPharma Inc

Zhuhai Trinomab Biotechnology Co Ltd

Beta Nerve Growth Factor (Beta NGF or NGF) – Drug Profiles

AK-115 – Drug Profile

Product Description

Mechanism Of Action

DS-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EP-9001A – Drug Profile

Product Description

Mechanism Of Action

fasinumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury – Drug Profile

Product Description

Mechanism Of Action

MEDI-7352 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis – Drug Profile

Product Description

Mechanism Of Action

MT-2 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RBM-004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Activate NGF Beta for Optic Nerve Injury – Drug Profile

Product Description

Mechanism Of Action

TNM-009 – Drug Profile

Product Description

Mechanism Of Action

TNM-010 – Drug Profile

Product Description

Mechanism Of Action

TNM-011 – Drug Profile

Product Description

Mechanism Of Action

udonitrectag – Drug Profile

Product Description

Mechanism Of Action

History of Events

Beta Nerve Growth Factor (Beta NGF or NGF) – Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF) – Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF) – Product Development Milestones

Featured News & Press Releases

Feb 10, 2022: Approval of clinical trial of NGF monoclonal antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain

Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA

Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints

Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis

Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug

May 12, 2010: Regeneron Provides Initial Data On REGN475

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Akeso Inc, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2022

Pipeline by Dartsbio Pharmaceutical (Guangdong) Co Ltd, 2022

Pipeline by Fujimoto Pharmaceutical Corp, 2022

Pipeline by MimeTech Srl, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Shandong Boan Biotechnology Co Ltd, 2022

Pipeline by Staidson BioPharma Inc, 2022

Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.